

**August 7, 2013, Mumbai, India**

## **GlaxoSmithKline Pharmaceuticals Quarter 2, 2013 Results**

---

GlaxoSmithKline Pharmaceuticals Limited announced its financial results for the second quarter ended June 30, 2013.

This quarter continued to be affected by constraints on supply in addition to impact on trade pipelines arising out of the implementation of the recently announced price changes pursuant to the new Drugs (Prices Control) Order. GSK expects supply constraints to be mitigated through the second half of year.

In the second quarter, the Company launched XGEVA, the first and only RANK Ligand inhibitor approved for the prevention of skeletal related events in patients with advanced malignancies involving bone.

### **About GlaxoSmithKline:**

GlaxoSmithKline Pharmaceuticals Limited is a subsidiary of GlaxoSmithKline plc, one of the world's leading research-based pharmaceutical and healthcare companies, committed to improving the quality of human life by enabling people to do more, feel better and live longer. For more information, visit [www.gsk-india.com](http://www.gsk-india.com).

### **For enquiries, please contact:**

Nandini Goswami  
General Manager, Corporate Communications

+91 22 24959203  
[nandini.x.goswami@gsk.com](mailto:nandini.x.goswami@gsk.com)